G R Bailie

Summary

Affiliation: Albany College of Pharmacy
Country: USA

Publications

  1. ncbi Hypersensitivity reactions and deaths associated with intravenous iron preparations
    George R Bailie
    Albany Nephrology Pharmacy ANephRx Group, Albany, NY, USA
    Nephrol Dial Transplant 20:1443-9. 2005
  2. ncbi Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects
    George R Bailie
    Albany Nephrology Pharmacy Group, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
    Nephrol Dial Transplant 20:1110-5. 2005
  3. ncbi From dialysis outcomes quality initiative to kidney disease outcomes quality initiative: new clinical practice guidelines in nephrology--what the practicing pharmacist needs to know
    George R Bailie
    Albany College of Pharmacy, Albany, New York 12208, USA
    Pharmacotherapy 24:551-7. 2004
  4. ncbi Therapeutic dilemmas in the management of peritonitis
    George R Bailie
    Albany Nephrology Pharmacy Group, Albany College of Pharmacy, New York, USA
    Perit Dial Int 25:152-6. 2005
  5. ncbi Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease
    George R Bailie
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Pharmacotherapy 25:491-502. 2005
  6. ncbi Analysis of medication use in peritoneal dialysis patients in two units
    George R Bailie
    Albany College of Pharmacy, Albany, New York, USA
    Perit Dial Int 25:287-90. 2005
  7. ncbi Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview
    George R Bailie
    Albany Nephrology Pharmacy ANephRx Group, Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208, USA
    Pharmacotherapy 25:1687-707. 2005
  8. ncbi Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    George R Bailie
    Albany College of Pharmacy, Albany, New York 12208, USA
    Hemodial Int 10:180-8. 2006
  9. ncbi Sexual dysfunction in dialysis patients treated with antihypertensive or antidepressive medications: results from the DOPPS
    George R Bailie
    Albany Nephrology Pharmacy ANephRx Group, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA, and Department of Internal Medicine, Koga Redcross Hospital, Ibaraki, Japan
    Nephrol Dial Transplant 22:1163-70. 2007
  10. ncbi Parenteral iron use in the management of anemia in end-stage renal disease patients
    G R Bailie
    Nephrology Pharmacy Associates, Inc, Ann Arbor, MI, USA
    Am J Kidney Dis 35:1-12. 2000

Detail Information

Publications33

  1. ncbi Hypersensitivity reactions and deaths associated with intravenous iron preparations
    George R Bailie
    Albany Nephrology Pharmacy ANephRx Group, Albany, NY, USA
    Nephrol Dial Transplant 20:1443-9. 2005
    ..We used the US Food and Drug Administration's Freedom of Information (FOI) surveillance database to compare the type 1 AE profiles for the three intravenous iron preparations available in the United States...
  2. ncbi Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects
    George R Bailie
    Albany Nephrology Pharmacy Group, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
    Nephrol Dial Transplant 20:1110-5. 2005
    ..We report on prescription data collected as part of a multicentre longitudinal study in patients with CKD, with a focus on medications with cardiovascular or cardioprotective effects...
  3. ncbi From dialysis outcomes quality initiative to kidney disease outcomes quality initiative: new clinical practice guidelines in nephrology--what the practicing pharmacist needs to know
    George R Bailie
    Albany College of Pharmacy, Albany, New York 12208, USA
    Pharmacotherapy 24:551-7. 2004
    ..This article provides a broad overview to the background of the development of CPGs in nephrology and the methodology used. Subsequent articles will identify in some detail current and pending CPGs that relate to pharmacotherapy...
  4. ncbi Therapeutic dilemmas in the management of peritonitis
    George R Bailie
    Albany Nephrology Pharmacy Group, Albany College of Pharmacy, New York, USA
    Perit Dial Int 25:152-6. 2005
  5. ncbi Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease
    George R Bailie
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Pharmacotherapy 25:491-502. 2005
    ..Also discussed are the association of level of kidney function with systemic complications that develop during CKD, and the risk of loss of kidney function and development of cardiovascular disease in CKD...
  6. ncbi Analysis of medication use in peritoneal dialysis patients in two units
    George R Bailie
    Albany College of Pharmacy, Albany, New York, USA
    Perit Dial Int 25:287-90. 2005
  7. ncbi Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview
    George R Bailie
    Albany Nephrology Pharmacy ANephRx Group, Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208, USA
    Pharmacotherapy 25:1687-707. 2005
    ..The problems and sequelae of soft-tissue calcification are discussed, and recommendations are provided for reducing the associated morbidity and mortality...
  8. ncbi Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    George R Bailie
    Albany College of Pharmacy, Albany, New York 12208, USA
    Hemodial Int 10:180-8. 2006
    ..5 g/dL. Prescription of GI medications was associated with many comorbidities and use of several medications. Extreme variability of prescription patterns suggests that there is no standard approach in treatment practices...
  9. ncbi Sexual dysfunction in dialysis patients treated with antihypertensive or antidepressive medications: results from the DOPPS
    George R Bailie
    Albany Nephrology Pharmacy ANephRx Group, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA, and Department of Internal Medicine, Koga Redcross Hospital, Ibaraki, Japan
    Nephrol Dial Transplant 22:1163-70. 2007
    ..The relationship between medication prescription and sexual dysfunction (SD) in dialysis patients is unclear...
  10. ncbi Parenteral iron use in the management of anemia in end-stage renal disease patients
    G R Bailie
    Nephrology Pharmacy Associates, Inc, Ann Arbor, MI, USA
    Am J Kidney Dis 35:1-12. 2000
    ..Currently available data suggest that iron sucrose and iron gluconate may have diminished adverse effect profiles when compared with iron dextran. Additional clinical experience will establish the role for these new iron products...
  11. ncbi Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription
    George R Bailie
    Albany College of Pharmacy, Albany, New York 12208, USA
    Kidney Int 65:2419-25. 2004
    ..Dialysis patients require special consideration regarding analgesics, given their altered pharmacokinetic and pharmacodynamic profiles and increased potential for adverse reactions...
  12. ncbi HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients
    Nancy A Mason
    College of Pharmacy, University of Michigan, College of Pharmacy, Ann Arbor, MI 48109 1065, USA
    Am J Kidney Dis 45:119-26. 2005
    ..This study examined statin prescription patterns and assessed the relationship between statin prescription and clinical outcomes in hemodialysis (HD) patients...
  13. ncbi Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project
    G R Bailie
    Center for Clinical Measurement and Improvement, Health Care Financing Administration, Albany, NY, USA
    Am J Kidney Dis 33:1187-9. 1999
    ..It is concluded that there could be improvement in the epoetin alfa and iron management in many patients...
  14. ncbi Comparative review of the pharmacokinetics of vitamin D analogues
    George R Bailie
    Albany College of Pharmacy, Albany, New York, USA
    Semin Dial 15:352-7. 2002
    ..More studies are warranted to determine the disposition of the vitamin D analogues, especially in selected populations such as pediatric and geriatric dialysis patients...
  15. ncbi Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS)
    Jennifer L Bragg-Gresham
    Arbor Research Collaborative for Health, formerly University Renal Research and Education Association, Ann Arbor, MI, USA
    Am J Kidney Dis 49:426-31. 2007
    ..Information about residual renal function (RRF) and outcomes associated with practices of diuretic use in patients with end-stage renal disease is not available worldwide...
  16. ncbi Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis
    Rowland J Elwell
    Albany Nephrology Pharmacy Group, Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208 3492, USA
    Perit Dial Int 25:380-6. 2005
    ..This study determined the pharmacokinetics of intraperitoneal (IP) cefepime in automated peritoneal dialysis (APD) patients...
  17. ncbi Hepatitis B vaccination: addressing a drug-related problem in hemodialysis outpatients with a collaborative initiative
    Rowland J Elwell
    Albany College of Pharmacy, Albany, NY, USA
    Nephrol Nurs J 30:310-3. 2003
    ..CONCLUSION: Given CDC guidelines, HBV vaccine should be offered to all HD patients. This initiative demonstrates that with concerted effort all consenting HD patients can receive HBV vaccination, thereby addressing an important DRP...
  18. ncbi Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: a retrospective cohort study
    Rowland J Elwell
    Department of Pharmacy Practice, Albany College of Pharmacy Albany, New York 12208, USA
    Pharmacotherapy 23:1558-63. 2003
    ..To assess the influence of various clinical factors on antibody production induced by hepatitis B vaccine in patients receiving hemodialysis up to 24 months after vaccination...
  19. ncbi Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125
    Harold J Manley
    School of Pharmacy, University of Missouri, Kansas City, MO, USA
    Ann Pharmacother 38:2035-40. 2004
    ..Human peritoneal mesothelial cells (HPMCs) may be affected by high IP cefazolin and ceftazidime concentrations. Peritoneal dialysate cancer antigen-125 (CA-125) appearance rate can be used to measure HPMC damage...
  20. ncbi Medication-related problems in ambulatory hemodialysis patients: a pooled analysis
    Harold J Manley
    Albany College of Pharmacy, Albany, NY 12208, USA
    Am J Kidney Dis 46:669-80. 2005
    ..We conducted a pooled analysis to gain additional insight into the frequency, type, and severity of medication-related problems and extrapolated the data to the entire US HD population...
  21. ncbi Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers
    K M Sowinski
    Department of Pharmacy Practice, School of Pharmacy and Pharmacal Sciences, Purdue University, Indianapolis, IN 46202 2879, USA
    Am J Kidney Dis 37:766-76. 2001
    ..Cefazolin doses of 15 or 20 mg/kg after each hemodialysis session maintained adequate serum concentrations throughout a 2- or 3-day interdialytic period regardless of hemodialyzer type...
  22. ncbi Rosiglitazone is associated with mortality in chronic hemodialysis patients
    Sylvia P B Ramirez
    Arbor Research Collaborative for Health, 315 W Huron, Ann Arbor, MI 48103, USA
    J Am Soc Nephrol 20:1094-101. 2009
    ..Our practice-based findings suggest significant associations of rosiglitazone use with higher cardiovascular and all-cause mortality among hemodialysis patients with diabetes...
  23. ncbi Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia
    George R Bailie
    Albany College of Pharmacy and Health Sciences, Albany, New York, USA
    Hemodial Int 14:47-54. 2010
    ..Administration of FCM (15 mg/kg, maximum of 1000 mg) over 15 minutes was well tolerated and associated with minimal risk of adverse reactions in patients with iron deficiency anemia...
  24. ncbi Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis
    Chaim Charytan
    New York Hospital of Queens, Flushing, NY, USA
    Nephron Clin Pract 100:c55-62. 2005
    ..Iron sucrose, given weekly as 200 mg IV push over 5 min is an effective and safe anemia treatment in this population...
  25. ncbi Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications
    George R Bailie
    Albany Nephrology Pharmacy ANephRx Group, Albany, New York, USA
    Arzneimittelforschung 60:386-98. 2010
    ..No safety concerns have been identified in breastfed infants of mothers receiving FCM. FCM is, therefore, an effective and well-tolerated option in the treatment of IDA...
  26. ncbi Safety of propoxyphene in dialysis patients
    George R Bailie
    Semin Dial 15:375. 2002
  27. ncbi Analysis of renal bone disease treatment in dialysis patients
    Curtis A Johnson
    Renal Network of the Upper Midwest, ESRD Network 11, St Paul, MN, USA
    Am J Kidney Dis 39:1270-7. 2002
    ..There is opportunity to improve renal osteodystrophy protocols in Network 11 and reinforce potential hazards of sustained hyperphosphatemia and hyperparathyroidism...
  28. ncbi Treatment of peritonitis in APD: pharmacokinetic principles
    Harold J Manley
    University of Missouri Kansas City, School of Pharmacy, Kansas City, Missouri 64108, USA
    Semin Dial 15:418-21. 2002
    ..Knowledge of antibiotic disposition in PD patients will assist clinicians in appropriate IP antibiotic dose selection and prevention of dose-related adverse effects...
  29. ncbi Peritoneal dialysis-related infections recommendations: 2005 update
    Beth Piraino
    University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Perit Dial Int 25:107-31. 2005
  30. ncbi Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolin
    Harold J Manley
    School of Pharmacy, University of Missouri Kansas City, Kansas City, Missouri 64108, USA
    Perit Dial Int 23:469-74. 2003
    ..To determine the impact of dialysate flow rate (DFR) on cefazolin pharmacokinetics (PK) in peritoneal dialysis (PD) patients...
  31. ncbi Iron and the anaemia of chronic disease: a review and strategic recommendations
    Ivor Cavill
    Medical School, Cardiff University, UK
    Curr Med Res Opin 22:731-7. 2006
    ..Improvement in the management of anaemia requires a fundamental change of attitude from healthcare professionals...
  32. ncbi Gentamicin pharmacokinetics during slow daily home hemodialysis
    Harold J Manley
    University of Missouri Kansas City, Kansas City 64108, USA
    Kidney Int 63:1072-8. 2003
    ..Slow daily home (SDH) hemodialysis (7 to 9 hours a day/6 days a week) use is increasing due to benefits observed with increased hemodialysis. We determined gentamicin pharmacokinetics for SDH hemodialysis patients...
  33. ncbi Delayed absorption and postdialysis rebound in a case of acute methanol poisoning
    Rowland J Elwell
    Am J Emerg Med 22:126-7. 2004